Keywords : Hepatitis B vaccine, Vaccine, therapeutic vaccine, Drug, engerix B, Recombivax HB, Pediarix, recombivax, twinrix
GlobalData, the market analysis specialist, has released its new report, “Hepatitis B - Pipeline Assessment and Industry Projections to 2017”. The report is an essential source of information and analysis on the global Hepatitis B therapeutics industry . The report identifies the major industry developments shaping and driving the global Hepatitis B therapeutics industry . The report also provides insights into the competitive landsc...
More »
Search ReportLinker
The Largest Collection of Market Research Reports
» 1.2 Million Industry Reports
» 450,000 Company Profiles
» 850,000 Market Briefings
» 40,000 Country Guides
From +200,000 authoritative sources
- Publication date: October 2011
- Report price: $ 3 500
GlobalData, the market analysis specialist, has released its new report, “Hepatitis B - Pipeline Assessment and Industry Projections to 2017”. The report is an essential source of information and analysis on the global Hepatitis B therapeutics industry . The report identifies the major industry developments shaping and driving the global Hepatitis B therapeutics industry . The report also provides insights into the competitive landscape and the emerging players expected to significantly alter the positions of the existing industry leaders. Most importantly, the report provides valuable insights into the new product development within the global Hepatitis B segment .
This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by Industry expert's team of market experts.
GlobalData estimates the global Hepatitis B (Hepatitis B) vaccine industry to be valued at USD 689m in 2009. The industry is estimated to grow up to USD 1.27bn in 2017, with a compound annual growth rate (CAGR) of 7.9%. This growth is attributed to the US and European regulatory approval of Heplisav in 2012. Growth in the Hepatitis B industry will be driven by the increase in the adult vaccines industry as a result of increasing public awareness.
Scope of the Research
The Scope of the Research of the report includes:
- Annualized global Hepatitis B therapeutics industry revenue data from 2001 to 2009, projection for eight years to 2017.
- Geographies covered in this report include the United States (US), the United Kingdom (UK), Italy, Spain, Germany, France and Japan.
- Pipeline analysis data providing a split across different phases, mechanisms of action being developed and emerging trends. The key classes of mechanism of action include nucleoside analogs, nucleotide analogs, immunoglobulins, TLR9 immunomodulators and immunoinducers.
- Analysis of the current and future industry competition in the global Hepatitis B vaccine industry . The key future industry players covered are GlaxoSmithkline, Merck & Co., Dynavax Technologies Corporation, PepTcell, LG Life Sciences, Genexine Co., Lipoxen PLC, Dong-A Pharmaceutical Co, ImmunoVaccine Technologies, GenPhar, Pfizer and NanoBio Corp.
- Insightful review of the key market drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include a strategic competitor assessment, a industry characterization, the unmet needs and the implications for the Hepatitis B industry .
Why Should You Get This Report?
The report will enhance your decision making capability. It will allow you to:
- Develop and design your in-licensing and out-licensing strategies through a review of new product development and technologies and by identifying the industry players with the most robust pipelines.
- Develop business strategies by understanding the trends shaping and driving the global Hepatitis B therapeutics industry .
- Drive revenues by understanding the major industry developments, innovative products and technologies, industry sectors and industry players likely to affect the global Hepatitis B therapeutics industry in the future.
- Formulate effective sales and industry ing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify the emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and industry ing efforts by identifying the industry categories and sectors that present the best opportunities for consolidation, investments and strategic partnerships.
- What’s the next big thing in the global Hepatitis B therapeutics industry landscape? Identify, understand and decide.
Drug And Medication Industry in the United Kingdom
1 Table of contents 3
I. 1 List of Data tables 4
I. 2 List of Charts 4
II Hepatitis B Vaccines: March ket Characterization 5
II. 1 Overview 5
II. 2 Hepatitis B Vaccines March ket Size 5
II. 3 Hepatitis B Vaccines March ket Forecasted data and CAGR 7
II. 4 Drivers and Barriers for Hepatitis B Vaccines March ket 8
II. 4.1 Drivers for Hepatitis B Vaccines March ket 8
II. 4.2 Barriers for Hepatitis B Vaccines March ket 8
II. 5 Opportunity and Unmet Need 9
II. 6 Key Takeaway 10
III Hepatitis B Vaccines March ket: Competitive Assessment 11
III. 1 Overview 11
III. 2 Strategic Competitor Assessment 11
III. 3 Product Profile for the Major March keted Vaccines in Hepatitis B March ket 12
III. 3.1 Recombivax HB 12
III. 3.2 Engerix-B 12
III. 3.3 Twinrix 13
III. 3.4 Comvax 14
III. 4 Major March keted Products Comparison in Hepatitis B Vaccines March ket 16
III. 5 Key Takeaway 17
IV Hepatitis B Vaccines March ket: Pipeline Assessment 18
IV. 1 Overview 18
IV. 2 Strategic Pipeline Assessment 18
IV. 2.1 Technology Trends Analytical Framework 18
IV. 3 Hepatitis B Vaccines Therapeutics – Promising Vaccines under Clinical Development 20
IV. 4 Molecule Profile for Promising Vaccines under Clinical Development 20
IV. 4.1 Heplisav 20
IV. 4.2 Spi-VEC 21
IV. 5 Hepatitis B Vaccines March ket – Clinical Pipeline by Vaccine Class 22
IV. 6 Hepatitis B Vaccines Pipeline – Pipeline by Clinical Phases of Development 23
IV. 6.1 Hepatitis B Vaccines Therapeutics – Phase III Clinical Pipeline 23
IV. 6.2 Hepatitis B vaccines Therapeutics – Phase II Clinical Pipeline 24
IV. 6.3 Hepatitis B Vaccines Therapeutics – Phase I Clinical Pipeline 24
IV. 6.4 Hepatitis B Vaccines Therapeutics – Preclinical Pipeline 24
IV. 6.5 Hepatitis B vaccines Therapeutics – Discovery Pipeline 24
IV. 7 Key Takeaway 25
5 World Hepatitis B Vaccines March ket: Implications for Future March ket Competition 26
6 World Hepatitis B Vaccines March ket: Future Players in Hepatitis B Vaccines March ket 28
VI. 1 Introduction 28
VI. 2 GlaxoSmithKline 28
VI. 2.1 Company Profile 28
VI. 2.2 Business Overview 29
VI. 3 Dynavax Technologies 29
VI. 3.1 Company Profile 29
VI. 3.2 Business Overview 29
VI. 4 Emergent BioSolutions Inc. 30
VI. 4.1 Company Profile 30
VI. 4.2 Business Overview 30
VI. 5 PepTcell Limited 31
VI. 5.1 Company Profile 31
VI. 5.2 Business Overview 31
VI. 6 Pfizer 31
VI. 6.1 Company Profile 31
VI. 6.2 Business Overview 32
7 World Hepatitis B Vaccines March ket: Appendix 33
VII. 1 Definitions 33
VII. 2 Acronyms 33
VII. 3 Research Methodology 33
VII. 3.1 Coverage 34
VII. 3.2 Secondary Research 34
VII. 3.3 Forecasted data ing 34
VII. 3.4 Primary Research 37
VII. 3.5 Expert Panel Validation 37
VII. 4 Contact Us 37
VII. 5 Disclaimer 37
VII. 6 Sources 38
1.1 List of Data tables
Data table 1: World Hepatitis B Vaccines March ket, Sales s (USD Million), from 2001 to 2009 6
Data table 2: Hepatitis B Vaccines March ket, Global, Sales s (USD Million) and Growth Rate (%), from 2009 to 2017 7
Data table 3: Major March keted Products Comparison in Hepatitis B Vaccines March ket, 2010 16
Data table 4: Hepatitis B Vaccines March ket, Most Promising Vaccines Under Clinical Development, 2010 20
Data table 5: Hepatitis B Vaccines March ket, Phase III Clinical Pipeline, 2010 23
Data table 6: Hepatitis B Vaccines March ket, Phase II Clinical Pipeline, 2010 24
Data table 7: Hepatitis B Vaccines March ket, Phase I Clinical Pipeline, 2010 24
Data table 8: Hepatitis B Vaccines March ket, Preclinical Pipeline, 2010 24
Data table 9: Hepatitis B Vaccines March ket, Discovery Pipeline, 2010 24
1.2 List of Charts
Chart 1: Hepatitis B Vaccines March ket, Global, Sales s (USD Million), from 2001 to 2009 6
Chart 2: Hepatitis B Vaccines March ket, Global, Sales s (USD Million), from 2009 to 2017 7
Chart 3: Opportunity and Unmet Need in the Hepatitis B Vaccines March ket, 2009 10
Chart 4: Strategic Competitor Assessment of the Hepatitis B Vaccines March ket, 2010 11
Chart 5: Hepatitis B Vaccines March ket, Technology Trends Analytic Framework, 2010 18
Chart 6: Hepatitis B Vaccines March ket, Technology Trends Analytic Framework, Description, 2010 19
Chart 7: Hepatitis B Vaccines Therapeutics March ket, Clinical Pipeline by Class of Vaccine (%), 2010 22
Chart 8: Hepatitis B Vaccines March ket, Pipeline by Phase of Clinical Development, 2010 23
Chart 9: Hepatitis B Vaccines March ket, Implications For Future Competition, 2010 26
Chart 10: Hepatitis B Vaccines March ket, Clinical Pipeline by Firms, 2010 28
Chart 11: GlobalData March ket Forecasted data ing Model 36
Companies mentionedGlaxoSmithKline
Dynavax Technologies
Emergent BioSolutions Inc.
PepTcell Limited
Pfizer
Vaccine in United Kingdom
- $ 250
- Industry data
- January 2013
Yearly, From 2003 To 2011
By Business Monitor International
Source: United Nations Comtrade Database DESA/UNSD, BMI
- Industries : Drug and Medication
- Countries : United Kingdom
- $ 250
- Industry data
- January 2013
Yearly, From 2002 To 2011
By Business Monitor International
Source: United Nations Comtrade Database DESA/UNSD, BMI
- Industries : Drug and Medication
- Countries : United Kingdom
- $ 250
- Industry data
- January 2013
Yearly, From 2003 To 2011
By Business Monitor International
Source: United Nations Comtrade Database DESA/UNSD, BMI
- Industries : Drug and Medication
- Countries : United Kingdom
- $ 250
- Industry data
- January 2013
Yearly, From 2003 To 2011
By Business Monitor International
Source: United Nations Comtrade Database DESA/UNSD, BMI
- Industries : Drug and Medication
- Countries : United Kingdom
- $ 250
- Industry data
- January 2013
Yearly, From 2002 To 2011
By Business Monitor International
Source: United Nations Comtrade Database DESA/UNSD, BMI
- Industries : Drug and Medication
- Countries : United Kingdom
Drug and Medication in United Kingdom
- $ 250
- Industry data
- January 2013
Yearly, From 2002 To 2021
By Business Monitor International
Source: IMS Health, Association of European Self-Medication Industry (AESGP), Department of Health, BMI
- Industries : Drug and Medication
- Countries : United Kingdom
- $ 250
- Industry data
- January 2013
Yearly, From 2003 To 2021
By Business Monitor International
Source: IMS Health, Association of European Self-Medication Industry (AESGP), Department of Health, BMI
- Industries : Drug and Medication
- Countries : United Kingdom
- $ 250
- Industry data
- January 2013
Yearly, From 2004 To 2021
By Business Monitor International
Source: IMS Health, Association of European Self-Medication Industry (AESGP), Department of Health, BMI
- Industries : Drug and Medication
- Countries : United Kingdom
- $ 250
- Industry data
- January 2013
Yearly, From 2005 To 2021
By Business Monitor International
Source: IMS Health, Association of European Self-Medication Industry (AESGP), Department of Health, BMI
- Industries : Drug and Medication
- Countries : United Kingdom
- $ 250
- Industry data
- January 2013
Yearly, From 2004 To 2021
By Business Monitor International
Source: IMS Health, Association of European Self-Medication Industry (AESGP), Department of Health, BMI
- Industries : Drug and Medication
- Countries : United Kingdom
- Publication date: October 2011
- Report price: $ 3 500
